Giovanni Crisafulli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5034285/publications.pdf

Version: 2024-02-01

39	3,482	361413	526287
papers	citations	20 h-index	27 g-index

41	41	41	6336
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
2	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	27.8	480
3	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
4	Adaptive mutability of colorectal cancers in response to targeted therapies. Science, 2019, 366, 1473-1480.	12.6	290
5	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer Discovery, 2016, 6, 36-44.	9.4	258
6	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical Cancer Research, 2015, 21, 2157-2166.	7.0	227
7	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature Communications, 2016, 7, 13665.	12.8	170
8	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer Cell, 2018, 34, 148-162.e7.	16.8	129
9	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
10	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open, 2017, 2, e000253.	4.5	56
11	Loss of AXIN1 drives acquired resistance to <scp>WNT</scp> pathway blockade in colorectal cancer cells carrying <scp>RSPO</scp> 3 fusions. EMBO Molecular Medicine, 2017, 9, 293-303.	6.9	54
12	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repairâ€“Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. Cancer Discovery, 2021, 11, 1923-1937.	9.4	48
13	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discovery, 2022, 12, 1656-1675.	9.4	48
14	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. Stem Cells, 2017, 35, 2218-2228.	3.2	47
15	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer, 2022, 127, 394-407.	6.4	41
16	Tracking aCAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of Oncology, 2017, 28, 1302-1308.	1.2	32
17	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British Journal of Cancer, 2017, 117, 347-352.	6.4	31
18	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. Clinical Colorectal Cancer, 2019, 18, 91-101.e3.	2.3	29

#	Article	IF	Citations
19	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. ESMO Open, 2019, 4, e000572.	4.5	27
20	A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. Nature Genetics, 2022, 54, 976-984.	21.4	23
21	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. Journal of Clinical Oncology, 2019, 37, TPS2659-TPS2659.	1.6	10
22	An extended multi-locus molecular typing schema for Streptococcus pneumoniae demonstrates that a limited number of capsular switch events is responsible for serotype heterogeneity of closely related strains from different countries. Infection, Genetics and Evolution, 2013, 13, 151-161.	2.3	9
23	Sequence Analysis of 96 Genomic Regions Identifies Distinct Evolutionary Lineages within CC156, the Largest Streptococcus pneumoniae Clonal Complex in the MLST Database. PLoS ONE, 2013, 8, e61003.	2.5	8
24	Tracking colorectal cancer evolution in time and space. Annals of Oncology, 2017, 28, 1163-1165.	1.2	5
25	Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth. Cancer Research, 2018, 78, 5723-5723.	0.9	5
26	Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2021, 39, 3589-3589.	1.6	2
27	Abstract PR01: Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer. , 2015, , .		1
28	Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. , 2016, , .		1
29	Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. , 2018, , .		1
30	Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies.. Journal of Clinical Oncology, 2015, 33, 11073-11073.	1.6	0
31	Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients. , 2015, , .		0
32	Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. , 2015, , .		0
33	Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade. , 2017, , .		0
34	Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers. , 2017, , .		0
35	Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer. , 2018, , .		0
36	Abstract B069: Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells. , 2019, , .		0

#	Article	IF	Citations
37	Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies. , 2019, , .		0
38	Abstract B11: Whole-exome sequencing analysis of urine transrenal tumor DNA in metastatic colorectal cancer patients. , 2020, , .		0
39	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomasâ€"A Preclinical and Translational Study. Cancers, 2021, 13, 6295.	3.7	0